bay 41-8543

BAY 41-8543 is a **novel, highly specific, and potent stimulator of soluble guanylate cyclase (sGC)** that acts independently of nitric oxide (NO)[1][3][5]. It directly stimulates sGC in a heme-dependent but NO-independent manner, increasing cyclic GMP within cells, and exhibits synergistic effects with endogenous NO[1][3]. BAY 41-8543 is a small molecule and was developed as a tool compound for cardiovascular research, particularly for investigating **vasodilation, antiplatelet, and antihypertensive effects**[1][3]. It has potent vasorelaxant effects on blood vessels and prevents platelet aggregation, acting via the cyclic GMP/protein kinase G/vasodilator-stimulated phosphoprotein (VASP) signaling pathway[1][3]. BAY 41-8543 has been explored as a potential therapy for cardiovascular diseases including hypertension and thrombosis and has beneficial effects in animal models of high blood pressure and endothelial dysfunction[3].

Other names

2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine